Hypoparathyroidism
Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH), leading to hypocalcemia and hyperphosphatemia. This condition results from underactivity or damage to the parathyroid glands, commonly due to surgical removal, radiation exposure, autoimmune destruction, or genetic mutations. Clinical manifestations include muscle cramps, tetany, seizures, weakness, headaches, excessive nervousness, and in children, weakened tooth enamel. Diagnosis is confirmed through blood tests showing low calcium and high phosphate levels, along with low PTH. Treatment primarily involves calcium and vitamin D supplementation, with recombinant human PTH available for refractory cases. Complications may include chronic kidney disease, cataracts, and neurological impairments if left untreated.
References:
-
Hypoparathyroidism (3)
Canvuparatide
Cat. No.: HY-P10909
CAS No.: 2925554-87-4
Synonyms: MBX 2109
- Formula: C263H441N65O81S2
- Molecular Weight: 5873.83
Canvuparatide (MBX 2109) is a PTH analog prodrug that releases the biologically active peptide through temperature- and pH-controlled intramolecular cyclization. The peptide released by Canvuparatide binds to and activates the PTH1 receptor, stimulating dose-dependent cAMP accumulation. Canvuparatide can be used in research on hypoparathyroidism.
PTH1R agonist 1
Cat. No.: HY-176943
CAS No.: 3106336-35-7
- Formula: C25H34N6O6
- Molecular Weight: 514.57
PTH1R agonist 1 (Example 2) is a parathyroid hormone 1 receptor (PTH1R) agonist. PTH1R agonist 1 can be used for research of hypoparathyroidism and osteoporosis.
PTH1R agonist 2
Cat. No.: HY-176944
CAS No.: 3106850-44-3
- Formula: C25H34N6O6
- Molecular Weight: 514.57
PTH1R agonist 2 (example 3) is a parathyroid hormone 1 receptor (PTH1R) agonist. PTH1R agonist 2 can be used for research of hypoparathyroidism and osteoporosis.
